CKH Food & Health Limited (900120) Fair Value & Analysis
Healthcare · KR · Market cap 40.7B KRW (≈ $28.5M) · ISIN KYG2114A1094
What is CKH Food & Health Limited really worth?
A solid business, but trading 414% above our fair value of 202.36 KRW.
Strengths
Risks
Fair value as of: Aug 13, 2026
From 24 valuation models · updated 21 days ago
Share price −11.0% over the past month.
What runs behind every stock
69 individual criteria per stock, every one traceable See the method →
What matters now
- The price sits above even our optimistic bull case (283.98 KRW). The favourable scenario is already priced in.
- The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution.
- Solid but not exceptional quality (61/100) and above fair value, neither a clear bargain nor a standout compounder.
- A fairly wide model range (136.75 KRW to 283.98 KRW) leaves room in how you read the outcome.
Price vs Fair Value (5 years)
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Aug 13, 2026.
How to read this chart
60‑month range 799.00 KRW – 23,600 KRW · fair‑value band 136.75 KRW – 283.98 KRW · the 1,040 KRW price screens above the 202.36 KRW fair value. Dashed = 300-day average. As of Aug 13, 2026.
Analysis
CKH Food & Health Limited (900120) currently trades at 1,040 KRW, while our model-based Fair Value estimate is 202.36 KRW, implying the stock looks roughly 413.9% overvalued today. The Quality Score stands at 61/100 (solid quality), in the Healthcare sector. Bull case: the Growth Earnings group reads highest at a median of 195.35 KRW per share, and 15 of the 24 models we run sit above the 1,040 KRW price. Bear case: the Multiples group reads lowest at 89.61 KRW, and 9 of the 24 models stay below the price. Evidence for this calculation is low.
Revenue declined 27.5% year over year. It earns a return on equity of 1.6%. Fundamentals as of Aug 13, 2026
Our scenario range runs from 136.75 KRW (bear case) to 283.98 KRW (bull case); at 1,040 KRW, the current price sits above that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades about 8% below its 52-week high and 221% above its 52-week low, currently above its 200-day average. For context, the median of 10 Healthcare peers we cover trades at −45% fair-value upside, at −81%, 900120 screens richer than that median.
Fair Value models
Each model estimates fair value its own way; the Fair Value above is the evidence-weighted, family-balanced blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small. Every input is real reported data, nothing guessed.
All 24 models by family
Widest divergence: Growth DCF (41,019 KRW) versus Dividend Discount (3.34 KRW). Highest evidence: FCF DCF (74).
Notify me when 900120 reaches fair value
Put 900120 on your watchlist. We get in touch as soon as price and fair value meet or the trend turns.
Set up alert →Free, no payment details. Unsubscribe anytime in one click.
Key figures & financial health
More key figures
Figures from reported company fundamentals · as of Aug 13, 2026. TTM = trailing twelve months.
Quality Score breakdown
Of which business quality 67 · Market factors (momentum, volatility) 12
Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.
All values are scores from 0 to 100 (100 = best against fixed, research-based bands), not percentages. The three market factors (momentum, 52-week proximity, low volatility) are displayed but carry zero weight in the headline number: market sentiment is not a business property.
About the company
CXI Healthcare Technology Group Limited engages in the manufacture and distribution of health foods. It provides Chinese medicine-based health supplements in capsule, tablet, drink, and tea forms. The company was formerly known as CKH Food & Health Limited and changed its name to CXI Healthcare Technology Group Limited in October 2023.
Full company description
CXI Healthcare Technology Group Limited engages in the manufacture and distribution of health foods. It provides Chinese medicine-based health supplements in capsule, tablet, drink, and tea forms. The company was formerly known as CKH Food & Health Limited and changed its name to CXI Healthcare Technology Group Limited in October 2023. CXI Healthcare Technology Group Limited was founded in 2009 and is based in Grand Cayman, the Cayman Islands.
Company description, as reported by the company or data provider.
Revenue & earnings trend
FY2020 – FY2024 · reported fiscal years
CKH Food & Health Limited reported revenue of 377M KRW in FY2024 versus 373M KRW in FY2020, a compound +0.3%/yr. Reported net income was 159M KRW in FY2024.
900120 screens 414% overvalued. Compare with Merck KGaA →
Peer Group
Drug Manufacturers - Specialty & Generic · 608 stocks
How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.
Valuation Multiples vs Drug Manufacturers - Specialty & Generic median · lower = cheaper
Strength profile in five axes (Snowflake)
Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.
VALUE 0: the price sits above our fair-value range.
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
Similar stocks
10 more Drug Manufacturers - Specialty & Generic stocks, each showing price versus our Fair Value estimate (as of Aug 13, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Merck KGaA MRK | €140.25 | €106.48 | −24% |
| Takeda Pharmaceutical Company TAK | $18.03 | $11.11 | −38% |
| Jiangsu Hengrui Pharmaceuticals Co 600276 | ¥53.76 | ¥25.94 | −52% |
| Sun Pharmaceutical Industries Limited SUNPHARMA | ₹1,944 | ₹989.50 | −49% |
| Galderma Group GALD | CHF 178.55 | CHF 55.07 | −69% |
| Haleon plc HLN | $10.11 | $7.64 | −24% |
| Teva Pharmaceutical Industries Limited TEVA | $36.05 | $15.33 | −57% |
| Sandoz Group SDZ | CHF 70.66 | CHF 39.21 | −45% |
| Zoetis Inc ZTS | $77.10 | $104.88 | +36% |
| Hansoh Pharmaceutical Group 3692 | HK$35.12 | HK$16.18 | −54% |
Compare CKH Food & Health Limited with another stock
Price, fair value, quality and upside side by side.
Explore undervalued stocks
More undervalued Healthcare stocks →
Try a ready-made strategy
Pick a strategy and jump into the live analysis with that exact screen applied.
Discover tools
Frequently asked questions
Is CKH Food & Health Limited (900120) overvalued or undervalued?
What is the fair value of 900120?
What is the quality score of 900120?
What is the net profit margin of 900120?
Does CKH Food & Health Limited pay a dividend?
Watch CKH Food & Health Limited in the live analysis
One click puts CKH Food & Health Limited on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
Watch for free →Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.